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Abstract: The prevalence of temporomandibular disorders (TMD) 
is higher in females, reaching their high peak during reproductive 
years, probably because of the action of some female hormones, 
which alter pain threshold. This study aimed to investigate 
the prevalence of TMD in postmenopausal women and its 
relationship with pain and hormone replacement therapy (HRT). 
In total, 284 patients were evaluated and classified using the 
Research Diagnostic Criteria for Temporomandibular Disorders 
(RDC/TMD). Pain was measured using the Visual Analogue Scale 
(VAS), and patients were also asked about the use of HRT. All data 
was analyzed using analysis of variance (ANOVA) and chi-square 
test. In total, 155 subjects did not have TMD and 129 had TMD; 
TMD group patients were classified according to RDC/TMD axis 
I classification as follows: muscle disorder group (1.6%), disk 
displacement group (72.87%), and arthralgia, osteoarthritis, and 
osteoarthrosis group (37.98%). Pain was registered in 35 patients 
who belonged to the TMD group, while 48 patients reported the 
use of HRT. There was a similar percentage of TMD and non 
TMD patients; moreover, the use of exogenous hormones was no 
associated with TMD, suggesting that there is no influence on the 
pain threshold.
Keywords: Temporomandibular Joint Disorders; Epidemiology; 
Postmenopausa; Facial Pain; Estrogen Replacement Therapy.
Introduction
Temporomandibular disorders (TMD) comprise a set of clinical 
conditions related to the temporomandibular joints (TMJ) and masticatory 
muscles of the face and neck. These conditions are frequently related 
to other structures of the body, complicating their classification, 
diagnosis, and treatment1,2,3.
The prevalence of TMD symptoms ranges from 16% to 59% in studies 
of non-patient populations4,5. On the other hand, clinical studies have 
reported higher prevalences (45% to 50%) and are more likely to identify 
severely affected patients6,7,8. Cross-sectional epidemiological studies of 
specific populations have shown that about 75% have at least one sign 
of TMD and about 33% have at least one symptom9,10, with pain being 
the predominant symptom.
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Approximately 7%–15% of the adult population 
in North America is afflicted with TMD11,12, and it 
is believed that approximately 6 million Brazilians 
have signs and symptoms of these disorders. Most, 
however, are not aware of the disorder that may be 
affecting them or of any sort of possible treatment 
or prognosis13.
Although the epidemiology of TMD has been 
studied6, reported prevalence rates vary broadly, 
reflecting important differences in samples, criteria, 
and methods used for collecting the information14,15.
Epidemiological studies suggest that symptoms 
related to TMD predominantly occur in young 
adults and in females14,16. Studies have reported 
a female:male ratio of approximately 4:1 in terms 
of the prevalence of TMD 10. Furthermore, this 
condition has the highest prevalence among women 
in their reproductive years (aged 20 to 40 years)17 and 
lowest prevalence among postmenopausal women, 
children, adolescents, and the elderly18,19. This higher 
prevalence among women has been attributed to 
inflammatory responses to stress, sociocultural 
behavior in response to pain, and effects related 
to hormonal characteristics14,16.
Several aspects of the prevalence pattern of TMD 
suggest that endogenous reproductive hormones play a 
role in these pain conditions, and various mechanisms 
explaining the influence of hormones in TMD pain 
can be postulated18. However, the exact mechanism 
of action of these hormonal effects remains unknown 
and is a matter of debate20,21.
The use of exogenous hormones and risk of TMD 
among postmenopausal women have been examined 
previously22. An examination of the records of a large 
health-maintenance organization revealed that the 
use of exogenous estrogen significantly increased the 
odds of having TMD. This study also reported that the 
probability of being a TMD case was approximately 
30% higher among women receiving estrogen than 
among those not receiving estrogen and concluded 
that the use of oral contraceptives is associated with 
an approximately 20% increased risk of TMD15.
Accordingly, the aim of this study was to assess 
and classify the prevalence of TMD in postmenopausal 
women and the relationship(s) between hormone 
replacement therapy (HRT), TMD, and pain.
Methodology
This study used data collected from 284 
postmenopausal women who were seeking different 
treatments at the Post-Graduation Clinic, Piracicaba 
Dental School, University of Campinas, between 
October 2013 and February 2015. The study was 
approved by the Ethics Committee of the Piracicaba 
Dental School, and all patients gave their informed 
consent to participate.
The sample-size requirement was calculated 
using standard formulas for finite population 
sampling, considering α = .05, β = .20, and a sampling 
error of 10%. The minimum sample size was 
estimated at 180 on the basis of data presented by 
Nekora-Azak et al.23
Four trained examiners were responsible for 
obtaining patient history and conducting the clinical 
examination, according to the RDC/TMD guidelines 
available on the RDC-TMD consortium website24 since 
2002. Patients who did not have a menstrual period 
for at least 12 consecutive months were included 
in the study; exclusion criteria were polyarthritis 
or other rheumatic disease or any other orofacial 
pain disorder.
For this study, only axis I of the RDC/TMD was 
considered, including three different diagnosis groups: 
muscle disorders (group I), disk displacement (group II), 
and arthralgia, osteoarthritis, and osteoarthrosis 
(group III). Patients were then classified as belonging to 
none, one, or more than one group, depending on the 
signs and symptoms identified through the history-
taking and clinical analysis conducted by more than 
one examiner at the same time.
After classification according to these RDC/TMD 
groups, patients were asked about the use of HRT using 
a question with a yes/no response, and the presence 
of pain was assessed in all patients using the Visual 
Analogue Scale (VAS). For VAS, each patient was 
presented with a paper on which a 10-cm-long line 
was drawn, marked at one end with 0 and at the 
other end with 10; the patients were asked to point 
to the position on the line that indicated the degree 
of pain they were feeling at the moment, considering 
0 as the absence of pain and 10 as the highest pain 
they could feel. The distance between 0 and the point 
indicated was measured and recorded.
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Analysis of variance (ANOVA) was used to analyze 
the frequency and mean age of patients with single and 
combined RDC/TMD axis I diagnoses. The correlation 
between the use of HRT and signs of pain was assessed 
using a chi-square test.
Results
Classifying the patients according to RDC/TMD 
yielded 155 subjects (54.58%) without TMD and 
129 subjects (45.42%) with TMD; their mean age 
was 56.7 years. Moreover, VAS testing identified 
249 patients (87.68%) with no pain symptoms and 
35 patients (12.32%) with moderate or severe pain 
symptoms. Among all these postmenopausal women, 
204 (71.83%) were not undergoing HRT and 80 (28.17%) 
were undergoing HRT (Figure 1).
Patients identified without TMD were also without 
pain. Among this TMD-negative group (total, 155), 42 
(27.10%) were undergoing HRT, whereas 113 (72.90%) 
were not undergoing any hormone treatment (Figure 
1). In contrast, 94 (72.87%) subjects identified as having 
TMD (total 129) reported no or low pain, whereas 35 
(27.13%) reported moderate to severe pain. In addition, 
46 (35.66%) were undergoing HRT and 83 (64.34%) were 
not receiving hormone treatment. From the TMD + pain 
group (35 subjects), 57.14% subjects were undergoing 
HRT, whereas 42.86% were not (Figure 1). The chi-
square test (p < 0.05) showed no significant differences 
between the use of HRT and signs of pain (Table 1).
On classifying the TMD-positive patients into the 
three RCD/TMD-defined TMD groups (one patient 
fell into more than one group), two patients (1.6%) were 
assigned to group I (muscle disorders), both (100%) of 
which reported pain symptoms; 94 patients (72.87%) 
were assigned to group II (disk displacement), 12.77% 
(12 patients) of which reported pain symptoms, while 
87.23% (82 patients) did not; and 49 patients (37.98%) were 
assigned to group III (arthralgia, osteoarthritis, and 
osteoarthrosis), 71.23% (35 patients) of which reported pain 
symptoms, while 28.57% (14 patients) did not (Figure 2).
The frequency and mean age of single and combined 
RDC/TMD diagnoses were calculated using ANOVA 
(p < 0.05); the results are shown in Table 2. Group 
I was not diagnosed alone; the disk displacement 
group (group II) consisted of 28 patients, 17% of which 
had a mean age of 57.71 ± 8.42 years, while group III 
consisted of 12 patients, 68% of which had a mean age 
of 58.28 ± 7.73 years. Three patients had combined 
diagnoses of disk displacements (group II) and arthralgia, 
osteoarthritis, and osteoarthrosis (group III); 87% of 
these had a mean age of 52.18 ± 6.95 years. Patients 
diagnosed in all groups together were present in 0, 7% 
of cases, with a mean age of 53.00 ± 2.83 years. No other 
diagnostic combinations were present in the study.
Table 2. Frequency and mean age of single and combined 
RDC/TMD axis I diagnoses in the study population.
RDC/TMD axis I group 
diagnoses
% Frequency Mean age*
No TMD 54.58 56.81 ± 9.33
I 0.0 -
II 28.17 57.71 ± 8.42
III 12.68 58.28 ± 7.73
I + II 0.0 -
I + III 0.0 -
II + III 3.87 52.18 ± 6.95
I + II + III 0.70 53.00 ± 2.83
*There were not significant differences in patients with single and 
combined diagnoses. 
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Figure 1. TMD, pain, and HRT relationship.
Table 1. Correlation between TRH use and signs of pain.
TRH 
Without 
TMD 
TMD  
without pain
TMD  
with pain
p-value
No 113 (72.90%) 68 (72.34%) 15 (42.86%) 0.1841
Yes 42 (27.10%) 26 (27.66%) 20 (57.14%)  
Chi-square test at a significance level set at 5%. 
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Discussion
It is well known that the prevalence of TMD is 
higher in females than in males15,25,26; this is probably 
due to the presence of certain gender hormones, 
which decrease after menopause, reducing TMD 
incidence27,28. There is a concern about the absence 
of TMD epidemiology involving postmenopausal 
women; this issue complicates the comparison of 
findings from different studies.
RDC/TMD is a standardized diagnostic guideline 
that helps in the assessment of patients with TMD29 
and has been the most widely employed protocol since 
199230. A new version, now called DC/TMD, has been 
released, but it was not available when this study was 
conducted. Although this new protocol provides some 
advantages over the old one, especially facilitating the 
diagnostics by clinicians, RDC/TMD has proved its 
reliability with different studies, including a multicenter 
one conducted by John et al.31. These data, in addition 
to the fact that the present study was performed by 
capacitated and trained researchers, support the 
reliability of the reported results.
This study revealed a similar percentage of women 
with TMD (54.58%) and without TMD (45.42%). In addition, 
only 27.13% of patients from the TMD group experienced 
some pain during clinical examination. 
Eighty-three patients from the TMD group (total, 
129 subjects) and 113 patients from the no TMD 
group (total, 155 subjects) were not under HRT, 
suggesting no relationship between the use of HRT 
and the presence of TMD; this fact is in accordance 
with that revealed in study of Nekora-Azak et al.23; 
that study revealed no differences in the relationship 
between postmenopausal hormone use and TMD 
in 180 postmenopausal women. Conversely, a study 
conducted by LeResche et al.17 contradicted this 
finding, indicating a strong evidence for a relationship 
between hormone use and TMD; it also mentioned 
that the relationships between hormone use and 
TMD would not be observed in a random sample 
of TMD cases identified in the community, which 
would be a limitation of the study.
LeResche et al.17 have also indicated the existence 
of an increased risk of TMD pain among women using 
various forms of exogenous hormones; this fact is 
contradictory to the findings of our study, where there 
was a similar percentage of HRT patients (57, 14%) and 
no HRT patients (42, 86%) in the TMD + pain group 
(35 subjects), suggesting no relationship between the use 
of exogenous hormones and TMD pain. It is probably due 
to the sample size and because those authors collected 
data from record forms, instead of performing clinical 
evaluations, as conducted in our study.
When classifying TMD patients (129 subjects) 
into RDC/TMD groups, most patients (72.87%) were 
classified into group II (disk displacement); probably 
this fact is because of an increase in intra-articular 
ligament laxity, which is related to aging; the minority 
of them (1.6%) were classified into group I (muscle 
disorders). In contrast, a study conducted with 
462 DTM patients by Manfredini et al.29 classified 
the majority of patients (57.5%) into group III and the 
minority of them (42%) into group II; the difference 
between these studies may be due to the age range 
of patient selection and the TMD sample size, which 
was one of the limitations of this study.
The authors consider that the sample size may 
have influenced in the results. Similarly, measuring 
hormone quantity by specific blood tests could provide 
more reliable results.
Further, others studies should be developed 
considering the application of RDC/TMD axis 
II to investigate the influence of behavioral and 
psychological factors on increase in pain22. The authors 
believe that more epidemiological studies should be 
conducted to confirm the results of the present study.
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Figure 2. RDC/TMD division groups and pain relationship.
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Conclussion
In summary, the group II (disk displacement) 
from the RDC/TMD axis I was diagnosed more 
frequently than the other two groups, indicating 
that disk displacement disorders tend to be more 
common with aging. In addition, TMD and the 
pain caused by this presence seem to have no 
relationship with the use of HRT, as suggested in 
some previous studies. More epidemiological studies 
should be developed, and the use of RDC/TMD 
axis II to evaluate behavioral and psychological 
factors is recommended. 
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